Molecular glue development continues to thrive, offering exciting opportunities to target previously undruggable proteins and treat a wide range of diseases. 2024 has seen a multitude of collaborations, with Takeda and Degron Therapeutics entering a deal worth $1.2 billion.

The 3rd Molecular Glue Drug Development Summit returns as the only industry-dedicated forum bringing together 90+ experts as they showcase the latest advancements and breakthroughs in molecular glue drug development through discussions and data-driven case studies on screening tools, novel mechanisms of actions of proximity-based degrading and non-degrading molecular glues and lead optimization strategies, to streamline discovery and development of safe and effective glues.

URLs:

Tickets: https://go.evvnt.com/2697860-2?pid=91

Brochure: https://go.evvnt.com/2697860-3?pid=91

Prices:

Drug Developer Pricing - Full Access Pass (Conference + 2 Workshops): USD 4197.00,

Drug Developer Pricing - 3 Day Pass (Conference + 1 Workshop): USD 3598.00,

Drug Developer Pricing - 2 Day Pass (Conference Only): USD 2999.00,

Academic Pricing - Full Access Pass (Conference + 2 Workshops): USD 3597.00,

Academic Pricing - 3 Day Pass (Conference + 1 Workshop): USD 3098.00,

Academic Pricing - 2 Day Pass (Conference Only): USD 2599.00,

Service and Solution Provider Pricing - Full Access Pass (Conference + 2 Workshops): USD 5097.00,

Service and Solution Provider Pricing - 3 Day Pass (Conference + 1 Workshop): USD 4398.00,

Service and Solution Provider Pricing - 2 Day Pass (Conference Only): USD 3699.00

Speakers: Andres Hernandez, de la Pena Principal Scientist, Neomorph, Andrew Potterton, Head of Technology Platform, Adhesion Therapeutics, Benedict Cross, Chief Technology Officer and Head of Platform, PhoreMost, Bin Liu, Chief Executive Officer, HB Therapeutics, Inc., Bradlee Heckmann, Co-founder and Chief Scientific Officer, ASHA therapeutics, Dmitri Ivanov, Associate Professor Biochemistry and Structural Biology, University of Texas Health San Antonio, **** Seok Kim, Chief Executive Officer, AevisBio Inc., Fan Liu, Co-Founder and Chief Technology Officer, NeoX Biotech Inc., Felix Hausch Professor, Technical University of Darmstadt, Feng Wang, Senior Principal Scientist and Lab Head Protein Homeostasis Discovery Sciences, Pfizer, Jacob Hale, Senior Scientist, Novartis, Julia Dou, Director of Protein Chemistry, Degron Therapeutics, Markus Queisser, Scientific Director, GlaxoSmithKline Plc, Matthew Hayward, Vice President of Drug Discovery, Magnet Biomedicine, Matthias Brand, Chief Technology Officer, Proxygen GmbH, Meizhong Jin, Senior Director - Oncology Chemistry, AstraZeneca, Peggy Thompson, Vice President and Head of Biology, Plexium Inc., Rana Quraishi, Chief Executive Officer, Isoprene Pharmaceuticals, Rick Ewing, Vice President and Head of Chemistry, Rapafusyn Pharmaceuticals, Tauseef ****, President and Chief Executive Officer, Progenra, Vivek Vishnudas, Vice President - Drug Discovery Non Clinical Development, Chief Technology Officer, Site Head of Research and Development, BPGBio Inc., Yao Wang, Chief Medical Officer, Kangpu Biopharmaceuticals